Related Experiment Video
Updated: Mar 26, 2026
07:56
A Full Skin Defect Model to Evaluate Vascularization of Biomaterials In Vivo
Published on: August 28, 2014
13.0K
All-comer treatment with bioresorbable vascular scaffold
Matjaž Bunc1, Miha Mrak2, Peter Rakovec3
1Department for Cardiology, University Medical Centre Ljubljana, Gubčeve brigade 11, SI-1000, Ljubljana, Slovenia.
Wiener Klinische Wochenschrift
|January 27, 2016
Summary
Bioresorbable vascular scaffolds (BVS) show promise for overcoming limitations of drug-eluting stents. This study found BVS implantation to be a safe treatment option with a low major adverse cardiac event rate in patients with noncomplex lesions.
Area of Science:
- Cardiovascular research
- Medical device technology
- Interventional cardiology
Background:
- Bioresorbable vascular scaffolds (BVS) offer a potential alternative to permanent drug-eluting stents (DES).
- Current BVS clinical studies are limited to noncomplex lesions, with no all-comer randomized trials.
- The permanent presence of DES in the vessel wall presents certain drawbacks.
Purpose of the Study:
- To evaluate the safety and efficacy of Bioresorbable Vascular Scaffolds (BVS) in a real-world patient cohort.
- To assess clinical outcomes including target vessel revascularization, mortality, and major adverse cardiac events.
- To investigate the safety of overlapping BVS and bare metal stents (BMS).
Main Methods:
- Retrospective analysis of 31 patients receiving at least one BVS (Absorb™) between September 2012 and November 2014.
- Median follow-up of 424 days.
- Monitoring for target vessel revascularization (TVR), target lesion revascularization (TLR), myocardial infarction (MI), death, and major adverse cardiac events (MACE).
Main Results:
- A low rate of target vessel revascularization (3.2%) was observed.
- The overall mortality rate was 6.5%, including one cardiac death due to acute stent thrombosis in a patient with overlapping BVS and BMS.
- No target lesion revascularization (TLR) or myocardial infarction (MI) occurred, resulting in a 3.2% MACE rate.
Conclusions:
- Bioresorbable vascular scaffold (BVS) implantation is a safe treatment modality.
- Careful patient selection and lesion preparation are crucial for successful BVS implantation.
- Further research is needed to understand the safety implications of overlapping BVS and bare metal stents (BMS).
